Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-8931 in prodromal Alzheimer's disease
NL-OMON44848Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of verubecestat in Alzheimer's disease (AD) (3 arms), sponsored by Merck & Co. Primary endpoint: Change from baseline in CDR-SB score at Week 104. Started Aug 2014; status: active, not recruiting.
02
Drugs
verubecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON44848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44848.